The complexity of p53 stabilization and activation

Cell Death and Differentiation

Volumn 13, Issue 6, 2006, Pages 941-950

  Lavin, Martin F ^a,b   Gueven, N ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cell cycle control; Cellular stress; Other factors; p53; Post translational modifications

Indexed keywords

DNA; DOUBLE STRANDED DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NUCLEOLIN; PROTEASOME; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RIBOSOME PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

5' UNTRANSLATED REGION; APOPTOSIS; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME ACTIVATION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN SYNTHESIS; REVIEW; SENESCENCE; STIMULUS RESPONSE; STRESS; TRANSCRIPTION INITIATION; UBIQUITINATION;

ACETYLATION; ANIMALS; APOPTOSIS; CELL CYCLE; DNA; DNA DAMAGE; HUMANS; MUTAGENS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 33646757232     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401925     Document Type: Review

References (101)

1. Kops GJ, Weaver BA and Clevand DW (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 10: 773-785.
2. Oren M (2001-2002) The p53 saga: The good, the bad, and the dead. Harvey Lect. 97: 57-82.
3. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N and TP53-CRC Collaborative Study Group (2005) The p53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 30: 7518-7528.
4. Steele RJ and Lane DP (2005) p53 in cancer. a paradigm for modern management of cancer. Surgeon 3: 197-205.
5. Steele RJ, Thompson AM, Hall PA and Lane DP (1998) The p53 tumour suppressor gene. Br. J. Surg. 11: 1460-1467.
6. Stark GR and Taylor WR (2004) Analysing the G2/M checkpoint. Methods Mol. Biol. 280: 51-82.
7. Tang W, Willers H and Powell SN (1999) p53 directly enhances rejoining of DNA double-strand breaks with cohesive ends in γ-irradiated mouse fibroblasts. Cancer Res. 59: 2562-2565.
8. Achanta G and Huang P (2004) Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species - generating agents. Cancer Res. 64: 6233-6239.
9. Navaraj A, Mori T and El- Diery WS (2005) Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers. Cancer Biol. Ther. 12: 1409-1414.
10. Lakin ND and Jackson SP (1999) Regulation of p53 in response to DNA damage. Oncogene 18: 7644-7655.
11. Harris SL and Levine AJ (2005) The p53 pathway: Positive and negative feedback loops. Oncogene 24: 2899-2908.
12. Maltzman W and Czyzyk L (1984) UV irradiation stimulates level of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4: 1689-1694.
13. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311.
14. Hammond EM, Denko NC, Dorie MJ, Abraham RT and Giaccia AJ (2002) Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 22: 1834-1843.
15. Suzuki K, Yokoyama S, Waseda S, Kodama S and Watanabe M (2003) Delayed reactivation of p53 in the progeny of cells surviving ionizing radiation. Cancer Res. 63: 936-941.
16. Jones KR, Elmore LW, Jackson-Cook C, Demasters G, Povirk LF, Holt SE and Gewirtz DA (2005) p53-dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int. J. Radial. Biol. 81: 445-458.
17. Ruggero D and Pandolfi PP (2003) Does the ribosome translate cancer? Nat. Rev. Cancer 3: 179-192.
18. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C and DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
19. Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber BL and El-Deiry WS (1998) BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16: 1713-1721.
20. Linke SP, Clarkin KC, Di Leonardo A, Tsou A and Wahl GM (1996) A reversible p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10: 934-947.
21. Milyavsky M, Mimran A, Senderovich S, Zurer I, Erez N, Shats I, Goldfinger N, Cohen I and Rotter V (2001) Activation of p53 protein by telomeric (TTAGGG) in repeats. Nucleic Acids Res. 29: 5207-5215.
22. Braithwaite AW, Royds JA and Jackson P (2005) The p53 story: Layers of complexity. Carcinogenesis 26: 1161-1169.
23. Banin S, Moyal L, Shieh S, Taya L, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281: 1674-1677.
24. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB and Siliciano JD (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679.
25. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y, Gabrielli B, Chan D, Lees-Miller SP and Lavin MF (1998) ATM associates with and phosphorylates p53: Mapping the region of interaction. Nat. Genet. 20: 398-400.
26. Saito S, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E and Anderson CW (2002) ATM mediates phosphorylation at multiple p53 sites, including Ser (46), in response to ionizing radiation. J. Biol. Chem. 277: 12491-12494.
27. 2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell. Biol. 21: 2743-2754.
28. Waterman MJ, Stavridi ES, Waterman JL and Halazonetis TD (1998) ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet. 19: 175-178.
29. Selivanova G, Kawasaki T, Ryabchenko L and Wiman KG (1998) Reactivation of mutant p53: A new strategy for cancer therapy. Semin. Cancer Biol. 8: 369-378.
30. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS and Kelly K (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175-1184.
31. Gu W and Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606.
32. Sagaguchi T, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW and Appella E (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12: 2831-2841.
33. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP and Pelicci PG (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207-210.
34. Gottifredi V and Prives C (2001) p53 and PML: New partners in tumor suppression. Trends Cell Biol. 11: 184-187.
35. Liu B, Situ Z, Wu J and Chen J (1999) Effects of hexamethylene bisacetamide on p53 protein expression of MeC-1 cell line and cell differentiation. Hua. Xi. Kou. Qiang. Yi. Xue. Za. Zhi. 17: 17-19.
36. Espinosa JM and Emerson BM (2001) Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8: 57-69.
37. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD and Berger SL (2001) Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8: 1243-1254.
38. Prives C and Manley JL (2001) Why is p53 acetylated? Cell 107: 815-818.
39. Gu L, Zhu N, Findley HW, Woods WG and Zhou M (2004) Identification and characterization of the IKKalpha promoter: Positive and negative regulation by ETS-1 and p53, respectively. J. Biol. Chem. 279: 52141-52149.
40. Krummel KA, Lee CJ, Toledo F and Wahl GM (2005) The C-terminal lysines fine-tune p53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. USA 102: 10188-10193.
41. Li M, Luo J, Brooks CL and Gu W (2002) Acetylation of p53 inhibits its ubiguition by Mdm2. J. Biol. Chem. 52: 50607-50611.
42. Apella E and Anderson CW (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268: 2764-2772.
43. Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fomace Jr AJ, Appella E and Anderson CW (2003) Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J. Biol. Chem. 278: 37536-37544.
44. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C and Del Sal G (2002) The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419: 853-857.
45. Ryan KM and Vousden KH (2002) Cancer. pinning a change on p53. Nature 419: 795-797.
46. Mantovani F, Gostissa M, Collavin L and Del Sal G (2004) KeePin' the p53 family in good shape. Cell Cycle 3: 905-911.
47. Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ and Herrlich P (1999) DNA damage induced p53 stabilization: No indication for an involvement of p53 phosphorylation. Oncogene 18: 1723-1732.
48. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N and Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
49. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, Wahl GM, Heimbrook DC and Vassilev LT (2004) Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 279: 53015-53022.
50. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R and Benchimol S (2003) Pirh2, a p53-induced ubiquitin-protein ligase promotes p53 degradation. Cell 112: 779-791.
51. Doman D, Eckert M, Wallace M, Shimizu H, Ramsay E, Hupp TR and Ball KL (2004) Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53. Mol. Cell. Biol. 24: 10083-10098.
52. Rajendra R, Malegaonkar D, Pungaliya P, Marshall H, Rasheed Z, Brownell J, Liu LF, Lutzker S, Saleem A and Rubin EH (2004) Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquinates p53. J. Biol. Chem. 279: 36440-36444.
53. Jones SN, Roe AE, Donehower LA and Bradley A (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
54. Fang S, Jensen JP, Ludwig RL, Vousden KH and Weissman AM (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275: 8945-8951.
55. Alarcon-Vargas D and Ronai Z (2002) p53-Mdm2 - the affair that never ends. Carcinogenesis 23: 541-547.
56. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y and Shkedy D (1999) Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl. Acad. Sci. USA. 96: 14973-14977.
57. Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, Moas M, Buschmann T, Ronai Z, Shiloh Y, Kastan MB, Katzir E and Oren M (2001) ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes Dev. 15: 1067-1077.
58. Wang Y, Wiltshire T, Wang Y, Mikell C, Burks J, Cunningham C, Van Laar ES, Waters SJ, Reed E and Wang W (2004) ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J. Biol. Chem. 279: 39584-39592.
59. Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD, Wang CY, Zambrowicz BP, Ramirez-Solis R, Sands AT and Zhang N (2002) MDMX is a negative regulator of p53 activity in vivo. Cancer Res. 62: 3221-3225.
60. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A and Ohtsubo M (1999) MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447: 5-9.
61. Jackson MW and Berberich SJ (2000) MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell. Biol. 20: 1001-1007.
62. Stad R, Little NA, Xirodimas DP, Frenk R, van der Eb AJ, Lane DP, Saville MK and Jochemsen AG (2001) Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2: 1029-1034.
63. Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G and Yuan ZM (2002) Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 277: 19251-19254.
64. Pereg Y, Shkedy D, de Graaf P, Meulmeester E, Edelson-Averbukh M, Salek M, Biton S, Teunisse AF, Lehmann WD, Jochemsen AG and Shiloh Y (2005) Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc. Natl. Acad. Sci. USA. 102: 5056-5061.
65. Chen L, Gilkes DM, Pan Y, Lane WS and Chen J (2005) ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 24: 3411-3422.
66. Okamoto K, Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A, Teunisse A, Migliorini D, Kitabayashi I, Marine JC, Prives C, Shiloh Y, Jochemsen AG and Taya Y (2005) DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol. Cell. Biol. 25: 9608-9620.
67. Meulmeester E, Pereg Y, Shiloh Y and Jochemsen AG (2005) ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favour of p53 activation. Cell Cycle 4: 1166-1170.
68. Laiho M and Latonen L (2003) Cell cycle control, DNA damage checkpoints and cancer. Ann. Med. 6: 391-397.
69. Sancar A, Lindsay-Boltz LA, Unsal-Kacmaz K and Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73: 39-85.
70. Lavin MF and Shiloh Y (1997) Ataxia-telangiectasia: A multifaceted genetic disorder associated with defective signal transduction. Curr. Opin. Immunol. 8: 459-464.
71. Lobrich M and Jeggo PA (2005) The two edges of the ATM sword: co-operation between repair and checkpoint functions. Radiother. Oncol. 76: 112-118.
72. Fuchs B, O'Connor D, Fallis L, Scheidtmann KH and Lu X (1995) p53 phosphorylation mutants retain transcription activity. Oncogene 10: 789-793.
73. Ito T, Kaneko K, Makino R, Ito H, Konishi K, Kurahashi T, Kitahara T and Mitamura K (2001) Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J. Gastroenterol. 36: 303-311.
74. Khanna KK and Lavin MF (1993) Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 8: 307-312.
75. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M and Haupt Y (1999) Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18: 1805-1814.
76. Jabbur JR, Huang P and Zhang W (2001) DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo. Oncogene 19: 6203-6208.
77. Yamauchi M, Suzuki K, Kodama S and Watanabe M (2004) Stabilization of alanine substituted p53 protein at Ser15, Thr18, and Ser20 in response to ionizing radiation. Biochem. Biophys. Res. Commun. 323: 906-911.
78. Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, Okada H, Sarkissian T, Wong JA, Sakai T, De Stanchina E, Bristow RG, Suda T, Lowe SW, Jeggo PA, Elledge SJ and Mak TW (2002) Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol. Cell. Biol. 22: 6521-6532.
79. Jack MT, Woo RA, Hirao A, Cheung A, Mak TW and Lee PW (2002) Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc. Natl. Acad. Sci. USA. 99: 9825-9829.
80. Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, Anderson CW, Appella E, Nakanishi M, Suzuki H, Nagashima K, Sawa H, Ikeda K and Motoyama N (2002) Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 21: 5195-5205.
81. Li M, Brooks CL, Kon N and Gu W (2004) A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13: 879-886.
82. Cummins JM and Vogelstein B (2004) HAUSP is required for p53 destabilization. Cell Cycle 3: 689-692.
83. Asher G, Lotem J, Sachs L, Kahana C and Shaul Y (2002) Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQ01. Proc. Natl. Acad. Sci. USA. 99: 13125-13130.
84. Asher G and Shaul Y (2005) p53 proteasomal degradation: poly-ubiquitination is not the whole story. Cell Cycle 4: 1015-1018.
85. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R and Brady JN (1998) Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 273: 33048-33053.
86. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E and Yao TP (2002) MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21: 6236-6245.
87. Demonacos C, Krstic-Demonacos M, Smith L, Xu D, O'Connor DP, Jansson M and La Thangue NB (2004) A new effector pathway links ATM kinase with the DNA damage response. Nat. Cell. Biol. 6: 968-976.
88. Nagashima M, Shiseki M, Miura K, Hagiwara K, Linke SP, Pedeux R, Wang XW, Yokota J, Riabowol K and Harris CC (2001) DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc. Natl. Acad. Sci. USA. 98: 9671-9676.
89. Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA and Reinberg D (2004) Regulation of p53 activity through lysine methylation. Nature 432: 353-360.
90. Rubbi CP and Milner J (2003) Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22: 6068-6077.
91. Colombo E, Marine JC, Danovi D, Falini B and Pelicci PG (2002) Nucleophosmin regulates the stability and transcriptional activity of p53. Nat. Cell Biol. 4: 529-533.
92. Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D and Laiho M (2004) Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5: 465-475.
93. Wang Y, Li J, Boder RN, Kraker A, Lawrence T, Leopold WA and Sun Y (2001) Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 61: 8211-8217.
94. Di Stefano V, Blandino G, Sacchi A, Soddu S and D'Orazi G (2004) HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. Oncogene 23: 5185-5192.
95. Rui Y, Xu Z, Lin S, Li Q, Rui H, Luo W, Zhou HM, Cheung PY, Wu Z, Ye Z, Li P, Han J and Lin SC (2004) Axin stimulates p53 functions by activation of HIPK2 knase through multimeric complex formation. EMBO J. 23: 4583-4594.
96. Wesierska-Gadek J, Bugajska-Schretter A, Low-Baselli A and Grasl-Kraupp B (1999) Cleavage of poly(ADP-ribose) transferase during p53-independent apoptosis in rat liver after treatment with N-nitrosomorpholine and cyproterone acetate. Mol. Carcinog. 24: 263-275.
97. Wesierska-Gadek J and Schmid G (2001) Poly (ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein. Cell. Mol. Biol. Lett. 6: 117-140.
98. Wesierska-Gadek J and Schmid G (2000) Overexpressed poly (ADP-ribose) polymerase delays the release of rat cells from p53-mediated G(1) checkpoint. J. Cell. Biochem. 80: 85-103.
99. Wieler S, Gagne JP, Vaziri H, Poirier GG and Benchimol S (2003) Poly (ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation. J. Biol. Chem. 278: 18914-18921.
100. Moumen A, Masterson P, O'Connor MJ and Jackson SP (2005) hnRNPK: An HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 123: 1065-1078.
101. Takagi M, Absalon MJ, McLure KG and Kastan MB (2005) Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123: 49-63.